Half-Year 2022 Financial and Clinical Trials Update

HY 2022: Diagnostics Division Strong core operating profit growth of +11% CER=Constant Exchange Rates 2022 2022 vs. 2021 CHFm % sales CER growth Sales 9,948 100 11% Royalties & other op. inc. 25 0.3 -46% Cost of sales -4,875 -49.1 14% M & D -1,363 -13.7 3% R & D -899 -9.0 11% G&A -276 -2.8 2% Core operating profit 2,560 25.7 11% +10% in CHF 50 39 Roche

View entire presentation